UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCRX
JHC
UBS Group's BCRX Position: Q3 2026 in Review
UBS Group increased its BioCryst Pharmaceuticals (BCRX) stake by 6% in Q3 2026, buying an estimated $2.89M and bringing the position to 5,385,432 shares worth $44.9M. The position accounts for 0.01% of the portfolio, ranked #1810.
UBS Group first reported a position in BCRX in Q4 2014 and has held it in 48 quarters since. The position peaked at $50.8M in Q2 2026. 334 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.
- UBS Group held 5,385,432 shares of BioCryst Pharmaceuticals worth $44.9M as of Q3 2026.
- UBS Group bought 307,152 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $2.89M.
- BioCryst Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q3 2026, its #1810 holding.
- UBS Group first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 48 quarters since.
- UBS Group's BioCryst Pharmaceuticals position peaked at $50.8M in Q2 2026.
- 334 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.